What is the optimal dosage of Bacillus subtilis ATCC 6051?

No standardized dosage has been established for this specific strain due to limited clinical research. General Bacillus subtilis supplements typically range from 1-10 billion CFU daily, but strain-specific studies are needed to determine optimal therapeutic doses.

How does Bacillus subtilis ATCC 6051 differ from other probiotic strains?

This strain specifically demonstrates antimicrobial activity with a 16.60 mm inhibition zone against E. coli and potential GABA production capability. Unlike vegetative probiotics, B. subtilis forms protective spores that survive stomach acid and harsh environmental conditions.

Can Bacillus subtilis ATCC 6051 survive stomach acid?

Yes, this strain forms endospores that protect it from gastric acid, bile salts, and digestive enzymes. The spores germinate in the alkaline environment of the small intestine, allowing the bacteria to colonize and exert probiotic effects.

What foods naturally contain Bacillus subtilis ATCC 6051?

This specific laboratory strain (ATCC 6051) is not naturally found in foods but is used in research and supplement formulations. Related B. subtilis strains occur naturally in fermented foods like natto, kimchi, and some traditional fermented vegetables.

How long does it take to see benefits from Bacillus subtilis ATCC 6051?

Due to limited human studies with this specific strain, onset timing is unclear. General probiotic research suggests digestive benefits may appear within 1-2 weeks, while immune effects typically require 4-8 weeks of consistent supplementation.

Is Bacillus subtilis ATCC 6051 safe for children and infants?

Bacillus subtilis ATCC 6051 is generally recognized as safe (GRAS) by the FDA for dietary use, making it suitable for children in age-appropriate doses. However, infants under 12 months should only receive probiotics under medical supervision, as their gut microbiome is still establishing. Consult a pediatrician before giving this strain to very young children or those with compromised immune systems.

Does Bacillus subtilis ATCC 6051 interact with antibiotics?

Bacillus subtilis ATCC 6051 may be less viable when taken simultaneously with broad-spectrum antibiotics, as antibiotics can suppress beneficial bacterial growth. To maximize effectiveness, consider spacing this probiotic 2–3 hours away from antibiotic doses when possible. Always inform your healthcare provider that you are taking this probiotic strain if you are prescribed antibiotics.

What does current clinical research show about Bacillus subtilis ATCC 6051's antimicrobial effectiveness?

In vitro studies have demonstrated antimicrobial activity against E. coli with a 16.60 mm inhibition zone, suggesting potential benefits for infection resistance. However, this strain-specific evidence comes primarily from laboratory studies, and human clinical trials are limited or absent. The gap between in vitro results and proven human efficacy means more rigorous clinical research is needed before making strong health claims.

Bacillus subtilis ATCC 6051

Bacillus subtilis ATCC 6051 is a probiotic bacterial strain that produces antimicrobial compounds and potentially synthesizes gamma-aminobutyric acid (GABA). This strain demonstrates antibacterial activity through the production of surfactin and other bioactive peptides that can inhibit pathogenic bacteria.

Category: Fermented/Probiotic Evidence: 2/10 Tier: Preliminary (in-vitro/animal)

Bacillus subtilis ATCC 6051 — Hermetica Encyclopedia

Origin & History

Bacillus subtilis ATCC 6051 (strain Marburg) is a Gram-positive, spore-forming bacterium originally isolated from soil as a wild-type laboratory strain without the auxotrophies seen in related strains. This probiotic candidate is cultured in media like MRS or LB broth for research and industrial applications, exhibiting robust growth and production of antimicrobial compounds during exponential phase.

Historical & Cultural Context

No historical or traditional medicine use is documented for Bacillus subtilis ATCC 6051, as it is a modern laboratory strain deposited with ATCC for 20th-century research applications. The strain has been used primarily for bacterial resistance testing and industrial applications rather than traditional therapeutic purposes.

Health Benefits

• Antimicrobial activity against E. coli with 16.60 mm inhibition zone in vitro studies (preliminary evidence only)
• Potential GABA production capability noted in research reports (no human trials available)
• May support infection resistance based on general B. subtilis animal models showing 30% survival vs. control death (strain-specific data lacking)
• Possible bovine mastitis control applications demonstrated in preclinical testing (veterinary evidence only)
• Genomic stability characteristics suggest safety as probiotic candidate (human safety data unavailable)

How It Works

Bacillus subtilis ATCC 6051 produces antimicrobial lipopeptides including surfactin, iturin, and fengycin that disrupt bacterial cell membranes and inhibit pathogen growth. The strain may also synthesize GABA through glutamate decarboxylase enzyme activity, converting L-glutamic acid to gamma-aminobutyric acid. These mechanisms contribute to gut microbiome balance and potential neurotransmitter modulation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses specifically on Bacillus subtilis ATCC 6051 were identified in the research. Evidence is limited to preclinical studies, with one report noting GABA-producing ability without human trial details, and in vitro antimicrobial testing showing activity against E. coli. Animal model studies exist only for general B. subtilis strains, not specifically ATCC 6051.

Clinical Summary

Current evidence for Bacillus subtilis ATCC 6051 is limited to preliminary in vitro studies showing a 16.60 mm inhibition zone against E. coli bacteria. Laboratory research indicates potential GABA production capability, though no human clinical trials have been conducted specifically with this strain. General Bacillus subtilis animal studies suggest 30% improvement in infection resistance, but strain-specific human data is lacking. More rigorous clinical research is needed to establish therapeutic efficacy and optimal dosing protocols.

Nutritional Profile

Bacillus subtilis ATCC 6051 is a gram-positive, spore-forming bacterium evaluated as a probiotic/fermentation agent rather than a direct nutritional source. As a microbial ingredient, its nutritional contribution is indirect. Cellular composition (based on general B. subtilis biomass data): Protein content approximately 40-60% of dry cell weight, primarily structural and enzymatic proteins including proteases and amylases. Lipid content approximately 5-10% dry weight, predominantly branched-chain fatty acids (iso-C15:0 and anteiso-C15:0 comprising ~65-70% of total fatty lipids), which are characteristic membrane stabilizers. Carbohydrate content approximately 10-20% dry weight, including cell wall teichoic acids and poly-gamma-glutamic acid capsular polymers. Bioactive compounds of functional relevance: produces iturin A, surfactin, and fengycin lipopeptides (antimicrobial compounds, concentrations vary by fermentation conditions, typically 10-500 mg/L in culture). Documented enzymatic activity includes protease, amylase, and lipase production, which may enhance substrate digestibility in fermented applications. GABA (gamma-aminobutyric acid) biosynthetic capacity has been noted via glutamate decarboxylase pathway, though quantified yield for ATCC 6051 specifically is not established in published literature; related strains produce 0.5-5 g/L GABA under optimized fermentation. Spore coat contains dipicolinic acid (5-15% of spore dry weight), contributing to heat and acid resistance relevant to gut survival. Vitamin synthesis: B. subtilis species broadly demonstrate menaquinone (Vitamin K2, MK-7 form) biosynthetic capacity, with yields of 20-40 mg/L reported in related strains; ATCC 6051-specific quantification is not confirmed in available literature. Bioavailability note: as a spore-former, ATCC 6051 demonstrates superior gastrointestinal survival compared to non-spore probiotics, with spore germination rates in the small intestine estimated at 30-60% based on general B. subtilis spore data, though strain-specific human GI transit data for ATCC 6051 is not currently published.

Preparation & Dosage

No clinically studied dosage ranges for human use of Bacillus subtilis ATCC 6051 are available, as it lacks human trials and is primarily a research strain. Preclinical studies used liquid cultures for antimicrobial testing without standardization of CFU counts or formulations for clinical use. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bacillus strains, Lactobacillus species, Prebiotics, GABA precursors, Antimicrobial herbs

Safety & Interactions

Bacillus subtilis ATCC 6051 is generally considered safe as it belongs to a species with GRAS (Generally Recognized as Safe) status. Potential side effects may include mild digestive upset, bloating, or gas during initial supplementation. No specific drug interactions have been documented, though caution is advised with immunosuppressive medications due to probiotic immune-modulating effects. Safety during pregnancy and lactation has not been established for this specific strain.